Newsfiscal.ai
MacroGenics Announces Positive Interim Phase 1 Results for MGC026
· Published
Article summary
MacroGenics reported positive interim data from its Phase 1 study of MGC026, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumors.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…